Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Androgen Receptor Signaling Reduces Radiosensitivity in Bladder Cancer.

Ide H, Inoue S, Mizushima T, Jiang G, Chuang KH, Oya M, Miyamoto H.

Mol Cancer Ther. 2018 Jul;17(7):1566-1574. doi: 10.1158/1535-7163.MCT-17-1061. Epub 2018 May 2.

2.

Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.

Kawahara T, Ide H, Kashiwagi E, El-Shishtawy KA, Li Y, Reis LO, Zheng Y, Miyamoto H.

Urol Oncol. 2016 Oct;34(10):432.e15-23. doi: 10.1016/j.urolonc.2016.05.016. Epub 2016 Jun 18.

PMID:
27330033
3.

ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.

Kawahara T, Shareef HK, Aljarah AK, Ide H, Li Y, Kashiwagi E, Netto GJ, Zheng Y, Miyamoto H.

Oncotarget. 2015 Oct 6;6(30):29860-76. doi: 10.18632/oncotarget.5007.

4.

Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.

Chou FJ, Chen Y, Chen D, Niu Y, Li G, Keng P, Yeh S, Chang C.

EBioMedicine. 2019 Feb;40:504-516. doi: 10.1016/j.ebiom.2018.12.050. Epub 2019 Jan 26.

5.

Epidermal growth factor induces bladder cancer cell proliferation through activation of the androgen receptor.

Izumi K, Zheng Y, Li Y, Zaengle J, Miyamoto H.

Int J Oncol. 2012 Nov;41(5):1587-92. doi: 10.3892/ijo.2012.1593. Epub 2012 Aug 21.

6.

Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis.

Izumi K, Zheng Y, Hsu JW, Chang C, Miyamoto H.

Mol Carcinog. 2013 Feb;52(2):94-102. doi: 10.1002/mc.21833. Epub 2011 Nov 15.

PMID:
22086872
7.

Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells.

Zheng Y, Izumi K, Yao JL, Miyamoto H.

Endocr Relat Cancer. 2011 Jul 4;18(4):451-64. doi: 10.1530/ERC-11-0010. Print 2011 Aug.

PMID:
21613411
8.

Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer.

Kashiwagi E, Ide H, Inoue S, Kawahara T, Zheng Y, Reis LO, Baras AS, Miyamoto H.

Oncotarget. 2016 Aug 2;7(31):49169-49179. doi: 10.18632/oncotarget.9994.

9.

Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.

Shang Z, Li Y, Zhang M, Tian J, Han R, Shyr CR, Messing E, Yeh S, Niu Y, Chang C.

Mol Cancer Ther. 2015 Nov;14(11):2586-94. doi: 10.1158/1535-7163.MCT-14-1055-T. Epub 2015 Aug 11.

10.

Androgen activates β-catenin signaling in bladder cancer cells.

Li Y, Zheng Y, Izumi K, Ishiguro H, Ye B, Li F, Miyamoto H.

Endocr Relat Cancer. 2013 May 20;20(3):293-304. doi: 10.1530/ERC-12-0328. Print 2013 Jun.

PMID:
23447569
11.

Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.

Hedayati M, Haffner MC, Coulter JB, Raval RR, Zhang Y, Zhou H, Mian O, Knight EJ, Razavi N, Dalrymple S, Isaacs JT, Santos A, Hales R, Nelson WG, Yegnasubramanian S, DeWeese TL.

Clin Cancer Res. 2016 Jul 1;22(13):3310-3319. doi: 10.1158/1078-0432.CCR-15-1147. Epub 2016 Feb 1.

12.

Promotion of bladder cancer development and progression by androgen receptor signals.

Miyamoto H, Yang Z, Chen YT, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang YJ, Hu YC, Tsai MY, Yeh S, Messing EM, Chang C.

J Natl Cancer Inst. 2007 Apr 4;99(7):558-68.

PMID:
17406000
13.

Corepressive function of nuclear receptor coactivator 2 in androgen receptor of prostate cancer cells treated with antiandrogen.

Takeda K, Hara N, Nishiyama T, Tasaki M, Ishizaki F, Tomita Y.

BMC Cancer. 2016 May 25;16:332. doi: 10.1186/s12885-016-2378-y.

14.

Inhibition of the Histone H3K27 Demethylase UTX Enhances Tumor Cell Radiosensitivity.

Rath BH, Waung I, Camphausen K, Tofilon PJ.

Mol Cancer Ther. 2018 May;17(5):1070-1078. doi: 10.1158/1535-7163.MCT-17-1053. Epub 2018 Feb 26.

15.

Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage.

Marampon F, Gravina G, Ju X, Vetuschi A, Sferra R, Casimiro M, Pompili S, Festuccia C, Colapietro A, Gaudio E, Di Cesare E, Tombolini V, Pestell RG.

Oncotarget. 2016 Feb 2;7(5):5383-400. doi: 10.18632/oncotarget.6579. Erratum in: Oncotarget. 2016 Sep 27;7(39):64526.

16.

Nuclear Factor-κB Promotes Urothelial Tumorigenesis and Cancer Progression via Cooperation with Androgen Receptor Signaling.

Inoue S, Ide H, Mizushima T, Jiang G, Netto GJ, Gotoh M, Miyamoto H.

Mol Cancer Ther. 2018 Jun;17(6):1303-1314. doi: 10.1158/1535-7163.MCT-17-0786. Epub 2018 Mar 28.

17.

Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.

Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM, Jenster G.

PLoS One. 2011;6(8):e23144. doi: 10.1371/journal.pone.0023144. Epub 2011 Aug 4.

18.

Chloroquine Enhances the Radiosensitivity of Bladder Cancer Cells by Inhibiting Autophagy and Activating Apoptosis.

Wang F, Tang J, Li P, Si S, Yu H, Yang X, Tao J, Lv Q, Gu M, Yang H, Wang Z.

Cell Physiol Biochem. 2018;45(1):54-66. doi: 10.1159/000486222. Epub 2017 Dec 22.

19.
20.

Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK.

Mol Cancer Ther. 2017 Jul;16(7):1389-1400. doi: 10.1158/1535-7163.MCT-17-0111. Epub 2017 May 3.

Supplemental Content

Support Center